Wells Fargo lowered the firm’s price target on NeuroPace (NPCE) to $13 from $15 and keeps an Overweight rating on the shares. The firm notes the company reported Q3 revenues well ahead of Wells’ and consensus estimates. Management increased revenue guidance for the year again, but held the line on OpEx andGM guidance, the firm adds.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks